GITR Antibodies in Cancer: Not Ready for Prime Time-Reference-Cited by-同舟云学术

GITR Antibodies in Cancer: Not Ready for Prime Time

Published:2022-07-14 Issue:18 Volume:28 Page:3905-3907
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Hernandez-Guerrero Tatiana¹^ORCID,Moreno Victor¹^ORCID

Affiliation:

1. 1START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain.

Abstract

Summary Glucocorticoid-induced TNF receptor (TNFR)-related protein (GITR) agonistic antibodies are expected to increase the antitumor response mainly by reducing the effect of Foxp3+ T-regulatory cells. TRX-518 is a novel GITR agonist that has shown good pharmacodynamic activity by depleting regulatory T cells (Tregs) in preclinical models, with limited clinical activity demonstrated in patients with advanced solid tumors. See related article by Davar et al., p. 3990

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-22-1489/3180429/ccr-22-1489.pdf

Reference13 articles.

1. Phase IB study of GITR agonist antibody TRX518 singly and in combination with gemcitabine, pembrolizumab or nivolumab in patients with advanced solid tumors;Davar;Clin Cancer Res,2022

2. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis;Nocentini;Proc Natl Acad Sci U S A,1997

3. GITR: A modulator of immune response and inflammation;Nocentini;Adv Exp Med Biol,2009

4. Enhancement of humoral and cellular immunity with an anti-glucocorticoid- induced tumour necrosis factor receptor monoclonal antibody;Ponte;Immunology,2010

5. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells;Ko;J Exp Med,2005

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms;Cancer Immunology, Immunotherapy;2024-05-02

2. Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells;Cancer Research;2024-04-18

3. A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance;Cancer Biology & Therapy;2024-02-02

4. Regulation of regulatory T cells and tumor‐associated macrophages in gastric cancer tumor microenvironment;Cancer Medicine;2024-01

5. Vaccine-induced effects on regulatory T cell function: autoimmune perspective;Regulatory T Cells and Autoimmune Diseases;2024